Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 210 results:
Author Title Type [ Year] Filters: Author is Athyros, Vasilios G [Clear All Filters]
Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study..
Curr Med Res Opin. 24(6), 1593-9.
(2008). Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?.
Expert Opin Ther Targets. 12(7), 809-20.
(2008). Has the time come for a new definition of microalbuminuria?.
Curr Vasc Pharmacol. 6(2), 81-3.
(2008). High density lipoprotein cholesterol and statin trials..
Curr Med Chem. 15(22), 2265-70.
(2008). Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas..
Endocr Relat Cancer. 15(3), 693-700.
(2008). Omega-3 fatty acids: how can they be used in secondary prevention?.
Curr Atheroscler Rep. 10(6), 510-7.
(2008). Preventing macrovascular complications of diabetes: where do we stand with glycemic control?.
Expert Opin Investig Drugs. 17(12), 1777-9.
(2008). Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?.
Expert Opin Pharmacother. 9(9), 1437-40.
(2008). Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism..
Expert Opin Pharmacother. 9(4), 509-15.
(2008). Statins for the prevention of first or recurrent stroke..
Curr Vasc Pharmacol. 6(2), 124-33.
(2008). Unusual manifestation of diarrhea-associated haemolytic uraemic syndrome in an adult..
Ren Fail. 30(3), 331-4.
(2008). Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?.
Expert Opin Pharmacother. 8(5), 529-35.
(2007). Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, CHD, stroke, and peripheral arterial disease in a Mediterranean cohort..
Angiology. 58(6), 689-97.
(2007). Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?.
Curr Pharm Des. 13(2), 229-39.
(2007). Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients..
Lipids. 42(11), 999-1009.
(2007). Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?.
Expert Opin Pharmacother. 8(14), 2267-77.
(2007). Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with CHD and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study..
Nephrol Dial Transplant. 22(1), 118-27.
(2007). Endothelial function, arterial stiffness and lipid lowering drugs..
Expert Opin Ther Targets. 11(9), 1143-60.
(2007). Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels..
Curr Drug Targets. 8(3), 483-8.
(2007). PCI and stable coronary heart disease--COURAGE to change our minds?.
Curr Vasc Pharmacol. 5(3), 173-4.
(2007). Pheochromocytoma: an update on genetics and management..
Endocr Relat Cancer. 14(4), 935-56.
(2007). Prevalence of vascular disease in metabolic syndrome using three proposed definitions..
Int J Cardiol. 117(2), 204-10.
(2007). The role of endocannabinoid system blockade in the treatment of the metabolic syndrome..
J Clin Pharmacol. 47(5), 642-52.
(2007). The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?.
Expert Opin Ther Targets. 11(2), 191-205.
(2007). Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients..
Open Cardiovasc Med J. 1, 8-14.
(2007).